京新藥業(002020.SZ):擬投資20.47億元建年產24702噸醫藥原料藥及中間體項目
格隆匯3月29日丨京新藥業(002020.SZ)公佈,為了提升公司在原料藥、醫藥高級中間體的市場競爭力,公司擬在山東省濰坊濱海經濟技術開發區綠色化工園投資新建醫藥健康全產業鏈生產基地(原料藥、醫藥中間體為主),項目總用地面積約1000畝,總投資約40億元,分期、分階段實施,並已與山東省濰坊濱海經濟技術開發區管委會簽署了《醫藥健康全產業鏈生產基地項目合同書》,該事項已經公司2019年第二次臨時股東大會審議通過。
為加快原料藥生產基地建設,公司全資子公司山東京新擬在於山東濰坊濱海經濟技術開發區大家窪街道綠色化工園投資建設原料藥基地一期項目——年產24702噸醫藥原料藥及中間體項目,總建築面積153752㎡,總投資估算204,696萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.